• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为被吸收的脱氧野尻霉素衍生物依米格列他(BAYo1248)抑制α-葡萄糖苷酶的结果,糖原在溶酶体中蓄积。一种药物诱导的肝糖原蓄积模式,类似于庞贝病(II型糖原贮积病)。

Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II).

作者信息

Lembcke B, Lamberts R, Wöhler J, Creutzfeldt W

机构信息

Division of Gastroenterology and Endocrinology, Georg-August-University, Göttingen, Federal Republic of Germany.

出版信息

Res Exp Med (Berl). 1991;191(6):389-404. doi: 10.1007/BF02576694.

DOI:10.1007/BF02576694
PMID:1775731
Abstract

Effects of the two absorbable alpha-glucosidase inhibitors miglitol (BAYm1099) and emiglitate (BAYo1248) on hepatic and muscular glycogen concentrations were investigated in the rat after 3, 7, and 28 days. Both compounds were (orally) administered at very high doses (5-50-500 mg/kg b.wt.). In a second experiment, glycogen storage after oral administration of acarbose (1000 mg/kg b.wt.) was studied after 7 days. In a third protocol, hepatic glycogen concentrations were investigated in the fed rat after 7 days of either inhibitor at the respective highest dosage. In fasted rats, emiglitate induced a significant, dose-dependent increase of hepatic glycogen concentrations, which--at the dose of 500 mg/kg b.wt.--were present after 3, 7, and 28 days, but resulted in a significant increase of the liver weight after 28 days only. Light and electron microscopy proved that the increase in hepatic glycogen was due to lysosomal storage of glycogen only. Emiglitate in the amount of 5 mg/kg b.wt. did not induce significant changes either of glycogen concentrations or at the EM-level. While emiglitate also increased hepatic glycogen at a dosage of 50 mg/kg b.wt., miglitol led to significant storage of hepatic glycogen after 3, 7, or 28 days at the highest dose only. With miglitol (500 mg/kg b.wt.), only insignificant lysosomal storage of glycogen could be detected by electron and light microscopy, and liver weight was essentially unaffected. Both compounds displayed a dose-dependent tendency towards higher glycogen concentrations in the soleus muscle, which was significant with the highest dosage of either inhibitor. At an oral dose of o.i.d. 1000 mg/kg b.wt., the almost unabsorbable alpha-glucosidase inhibitor acarbose induced significantly increased glycogen concentrations both in the liver and in the soleus muscle after 7 days. With respect to an enormous enlargement of the lysosomes (EM) and in the absence of cytoplasmatic alpha-glycogen, this accumulation of glycogen must be attributed to lysosomal storage. In fed rats, all alpha-glucosidase inhibitors investigated significantly decreased postprandial hepatic glycogen concentrations (emiglitate greater than miglitol greater than acarbose), thereby reflecting the modulation of absorption. It is concluded that in the rat acarbose at approximately 1000 x ED50 may penetrate the intestinal mucosa at amounts significant enough to induce lysosomal storage of glycogen. Miglitol may cause some hepatocellular, lysosomal glycogen storage at a dose of 500 mg/kg b.wt., but no glycogen storage could be proven up to 100 x ED50 over 28 days.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

研究了两种可吸收的α-葡萄糖苷酶抑制剂米格列醇(BAYm1099)和依米格列他(BAYo1248)在大鼠体内作用3、7和28天后对肝脏和肌肉糖原浓度的影响。两种化合物均以非常高的剂量(5 - 50 - 500 mg/kg体重)口服给药。在第二个实验中,研究了口服阿卡波糖(1000 mg/kg体重)7天后的糖原储存情况。在第三个实验方案中,在分别给予两种抑制剂各自最高剂量7天后,研究了喂食大鼠的肝脏糖原浓度。在禁食大鼠中,依米格列他可引起肝脏糖原浓度显著的剂量依赖性增加,在500 mg/kg体重剂量下,3天、7天和28天后均出现此现象,但仅在28天后导致肝脏重量显著增加。光镜和电镜检查证明肝脏糖原增加仅是由于糖原的溶酶体储存。5 mg/kg体重剂量的依米格列他对糖原浓度或电镜水平均未引起显著变化。虽然50 mg/kg体重剂量的依米格列他也增加了肝脏糖原,但米格列醇仅在最高剂量下3天、7天或28天后导致肝脏糖原显著储存。对于米格列醇(500 mg/kg体重),通过电子显微镜和光镜仅检测到极少量的糖原溶酶体储存,肝脏重量基本未受影响。两种化合物均呈现出在比目鱼肌中糖原浓度随剂量增加的趋势,两种抑制剂的最高剂量时此趋势显著。口服剂量为1000 mg/kg体重时,几乎不吸收的α-葡萄糖苷酶抑制剂阿卡波糖在7天后可显著增加肝脏和比目鱼肌中的糖原浓度。鉴于溶酶体极大增大(电镜检查)且缺乏细胞质α-糖原,这种糖原积累必定归因于溶酶体储存。在喂食大鼠中,所有研究的α-葡萄糖苷酶抑制剂均显著降低餐后肝脏糖原浓度(依米格列他>米格列醇>阿卡波糖),从而反映了对吸收的调节作用。结论是,在大鼠中,约1000倍ED50剂量的阿卡波糖可能以足以诱导糖原溶酶体储存的量穿透肠黏膜。米格列醇在500 mg/kg体重剂量时可能导致一些肝细胞溶酶体糖原储存,但在28天内高达100倍ED50剂量时未证实有糖原储存。(摘要截断于400字)

相似文献

1
Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II).作为被吸收的脱氧野尻霉素衍生物依米格列他(BAYo1248)抑制α-葡萄糖苷酶的结果,糖原在溶酶体中蓄积。一种药物诱导的肝糖原蓄积模式,类似于庞贝病(II型糖原贮积病)。
Res Exp Med (Berl). 1991;191(6):389-404. doi: 10.1007/BF02576694.
2
Lysosomal glycogen storage mimicking the cytological picture of Pompe's disease as induced in rats by injection of an alpha-glucosidase inhibitor. I. Alterations in liver.注射α-葡萄糖苷酶抑制剂诱导大鼠产生的溶酶体糖原贮积症,其细胞学表现类似庞贝氏病。I. 肝脏的变化
Virchows Arch B Cell Pathol Incl Mol Pathol. 1981;38(1):89-100. doi: 10.1007/BF02892805.
3
Lysosomal glycogen storage induced by Acarbose, a 1,4-alpha-glucosidase inhibitor.阿卡波糖(一种1,4-α-葡萄糖苷酶抑制剂)诱导的溶酶体糖原贮积。
Biochem J. 1985 Jun 1;228(2):319-24. doi: 10.1042/bj2280319.
4
Lysosomal glycogen accumulation in rat liver and its in vivo kinetics after a single intraperitoneal injection of acarbose, an alpha-glucosidase inhibitor.大鼠肝脏中溶酶体糖原的积累及其在单次腹腔注射α-葡萄糖苷酶抑制剂阿卡波糖后的体内动力学
J Biochem. 1990 Feb;107(2):197-201. doi: 10.1093/oxfordjournals.jbchem.a123025.
5
An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus.
Eur J Clin Invest. 1994 Aug;24 Suppl 3:19-24. doi: 10.1111/j.1365-2362.1994.tb02251.x.
6
1-Deoxynojirimycin and related compounds inhibit glycogenolysis in the liver without affecting the concentration of phosphorylase a.1-脱氧野尻霉素及相关化合物可抑制肝脏中的糖原分解,而不影响磷酸化酶a的浓度。
Biochem Pharmacol. 1988 Mar 1;37(5):905-9. doi: 10.1016/0006-2952(88)90179-7.
7
Disturbance of lysosomal glycogen metabolism by liposomal anti-alpha-glucosidase and some anti-inflammatory drugs.脂质体抗α-葡萄糖苷酶和一些抗炎药物对溶酶体糖原代谢的干扰。
Biochem J. 1983 Apr 15;212(1):99-103. doi: 10.1042/bj2120099.
8
Lysosomal glycogen storage mimicking the cytological picture of Pompe's disease as induced in rats by injection of an alpha-glycosidase inhibitor. II. Alterations in kidney, adrenal gland, spleen and soleus muscle.
Virchows Arch B Cell Pathol Incl Mol Pathol. 1982;39(2):187-202. doi: 10.1007/BF02892847.
9
The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?口服葡萄糖负荷后米格列醇和阿卡波糖的作用:一种新的降血糖机制?
Br J Clin Pharmacol. 1990 Sep;30(3):391-6. doi: 10.1111/j.1365-2125.1990.tb03789.x.
10
Inhibition of sucrose- and starch-induced glycaemic and hormonal responses by the alpha-glucosidase inhibitor emiglitate (BAY o 1248) in healthy volunteers.α-葡萄糖苷酶抑制剂依米格列他(BAY o 1248)对健康志愿者蔗糖和淀粉诱导的血糖及激素反应的抑制作用。
Eur J Clin Pharmacol. 1991;41(6):561-7. doi: 10.1007/BF00314985.

引用本文的文献

1
Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients.晚期慢性肾病患者接受α-葡萄糖苷酶抑制剂治疗后发生肝损伤的风险。
Sci Rep. 2016 Jan 11;6:18996. doi: 10.1038/srep18996.
2
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.米格列醇:对其在2型糖尿病中治疗潜力的综述。
Drugs. 2000 Mar;59(3):521-49. doi: 10.2165/00003495-200059030-00012.
3
Disposition of glycosidase inhibitors in the isolated perfused rat liver: hepatobiliary and subcellular concentration gradients of 1-deoxymannojirimycin and N-methyl-1-deoxynojirimycin.
糖苷酶抑制剂在离体灌注大鼠肝脏中的处置:1-脱氧野尻霉素和N-甲基-1-脱氧野尻霉素的肝胆及亚细胞浓度梯度
Pharm Res. 1994 Jan;11(1):144-50. doi: 10.1023/a:1018970400323.